Why is this overlooked FTSE 100 stock leading the market?

This FTSE 100 stock has been lagging behind the index for six months. But it’s just turned upwards on the release of positive news.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Smiths Group (LSE: SMIN) led the FTSE 100 by midday Tuesday, on a day when most stocks in the top index were losing ground. Shares in the engineering group, bucking the trend, gained 4% as the biggest morning winner.

Smiths has traditionally been involved in a number of engineering sectors. That includes aerospace, defence, and medical equipment. The company has now confirmed the sale of Smiths Medical to ICU Medical, Inc. The division had been up for sale for a while, with a previous deal with TA Associates on the cards.

Then on 8 September, Smiths announced a new agreement with ICU that would realise greater value. The company put the net value at $2.4bn, approximately $0.4bn higher than the TA transaction.

The confirmation came on the same day Smiths released full-year results, headlined “Stronger H2 performance; good momentum“.

Underlying revenue fell 2% for the year, but it’s turning around. The second half came in flat, while the company recorded revenue growth in the final quarter. But even if revenue growth was not sparkling, Smiths’ conversion of it into profit looks good.

Profit rising

Operating profit gained 7%, with operating margin improving by 1.4 percentage points. At a time when a lot of FTSE 100 firms are suffering margin squeezes, that’s a welcome change. First-half underlying EPS increased by 8%, and the board has lifted the full-year dividend by the same proportion to 26p per share.

On the current Smiths share price, the dividend yield comes in at 1.8%. That’s a modest yield, but it’s covered more than 3.5 times by earnings. I’d much rather see a modest-but-well-covered dividend from a company with strong cash flow than a big yield from a firm under intense balance sheet pressure.

On the cash front, Smiths recorded free cash flow of £383m, an increase of 40%. Net debt stood at £1,018m at 31 July. That’s a net-debt-to-EBITDA multiple of 1.6x (even including one-off restructuring costs). For a £5.6bn company with annual revenue of £2.4bn, that’s good enough for me.

Lagging the FTSE 100

Why do I rate Smiths as an overlooked FTSE 100 stock? Well, I previously had the company pegged as one to watch in September. It seemed at the time that investors weren’t too please by the upcoming Medical division sale. The Smiths share price has dipped below the FTSE 100 over the past six months. And it’s still down 18% since pandemic week in February 2020. Perhaps it’s got something to do with valuation.

On depressed 2020 earnings, the stock had been looking a bit hotly valued in terms of its P/E ratio. Even on pre-pandemic 2019 earnings, the current Smiths share price suggests a multiple of above 20. But on the underlying earnings the company has just delivered, we’re looking at a P/E of only around 15 now.

Outlook vs risks

The company reckons it has good order book momentum, and it expects revenue to return to pre-Covid levels during the current year. With improved operational efficiency too, the current valuation looks good to me.

There’s a downside, though. In the UK we’re facing increasing supply chain problems. And our economy still looks a bit fragile, with inflation set to climb above 4%. Those uncertainties, I fear, might keep Smiths Group overlooked for a while longer. I’d buy today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »